Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

A GPS Phase-Locked Loop Performance Metric Based on the Phase Discriminator Output.

Stevanovic S, Pervan B.

Sensors (Basel). 2018 Jan 19;18(1). pii: E296. doi: 10.3390/s18010296.

2.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1403022. [Epub ahead of print]

PMID:
29295645
3.

Correction for Ebner et al., "Excreted Cytoplasmic Proteins Contribute to Pathogenicity in Staphylococcus aureus".

Ebner P, Rinker J, Nguyen MT, Popella P, Nega M, Luqman A, Schittek B, Di Marco M, Stevanovic S, Götz F.

Infect Immun. 2017 Nov 17;85(12). pii: e00641-17. doi: 10.1128/IAI.00641-17. Print 2017 Dec. No abstract available.

4.

Characterizing pollutant emissions from mosquito repellents incenses and implications in risk assessment of human health.

Wang L, Zheng X, Stevanovic S, Xiang Z, Liu J, Shi H, Liu J, Yu M, Zhu C.

Chemosphere. 2018 Jan;191:962-970. doi: 10.1016/j.chemosphere.2017.09.097. Epub 2017 Oct 22.

PMID:
29145141
5.

The immunopeptidomic landscape of ovarian carcinomas.

Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.

6.

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

Rausch S, Gouttefangeas C, Hennenlotter J, Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja H, Frick A, Kröger N, Stevanović S, Stenzl A, Rammensee HG, Bedke J.

Eur Urol Focus. 2017 Oct 4. pii: S2405-4569(17)30213-4. doi: 10.1016/j.euf.2017.09.009. [Epub ahead of print]

PMID:
28988765
7.

The SysteMHC Atlas project.

Shao W, Pedrioli PGA, Wolski W, Scurtescu C, Schmid E, Vizcaíno JA, Courcelles M, Schuster H, Kowalewski D, Marino F, Arlehamn CSL, Vaughan K, Peters B, Sette A, Ottenhoff THM, Meijgaarden KE, Nieuwenhuizen N, Kaufmann SHE, Schlapbach R, Castle JC, Nesvizhskii AI, Nielsen M, Deutsch EW, Campbell DS, Moritz RL, Zubarev RA, Ytterberg AJ, Purcell AW, Marcilla M, Paradela A, Wang Q, Costello CE, Ternette N, van Veelen PA, van Els CACM, Heck AJR, de Souza GA, Sollid LM, Admon A, Stevanovic S, Rammensee HG, Thibault P, Perreault C, Bassani-Sternberg M, Aebersold R, Caron E.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1237-D1247. doi: 10.1093/nar/gkx664.

8.

Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices.

Di Marco M, Schuster H, Backert L, Ghosh M, Rammensee HG, Stevanović S.

J Immunol. 2017 Oct 15;199(8):2639-2651. doi: 10.4049/jimmunol.1700938. Epub 2017 Sep 13.

PMID:
28904123
9.

Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.

Kang Z, Stevanović S, Hinrichs CS, Cao L.

Clin Cancer Res. 2017 Nov 15;23(22):6856-6862. doi: 10.1158/1078-0432.CCR-17-1553. Epub 2017 Sep 12.

PMID:
28899967
10.

Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells.

Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stölzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M.

Haematologica. 2017 Nov;102(11):e460-e464. doi: 10.3324/haematol.2017.167312. Epub 2017 Aug 24. No abstract available.

11.

TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway.

Neerincx A, Hermann C, Antrobus R, van Hateren A, Cao H, Trautwein N, Stevanović S, Elliott T, Deane JE, Boyle LH.

Elife. 2017 Apr 20;6. pii: e23049. doi: 10.7554/eLife.23049.

12.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.

Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS.

Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.

PMID:
28408606
13.

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.

Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN.

Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.

14.

Biomimetic Remineralization of Carious Lesions by Self-Assembling Peptide.

Kind L, Stevanovic S, Wuttig S, Wimberger S, Hofer J, Müller B, Pieles U.

J Dent Res. 2017 Jul;96(7):790-797. doi: 10.1177/0022034517698419. Epub 2017 Mar 27.

PMID:
28346861
15.

Role of Chinese cooking emissions on ambient air quality and human health.

Wang L, Xiang Z, Stevanovic S, Ristovski Z, Salimi F, Gao J, Wang H, Li L.

Sci Total Environ. 2017 Jul 1;589:173-181. doi: 10.1016/j.scitotenv.2017.02.124. Epub 2017 Mar 3.

PMID:
28262368
16.

MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies.

Murphy JP, Konda P, Kowalewski DJ, Schuster H, Clements D, Kim Y, Cohen AM, Sharif T, Nielsen M, Stevanovic S, Lee PW, Gujar S.

J Proteome Res. 2017 Apr 7;16(4):1806-1816. doi: 10.1021/acs.jproteome.6b00971. Epub 2017 Mar 21.

PMID:
28244318
17.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

18.

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.

Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O.

PLoS One. 2016 Nov 28;11(11):e0167017. doi: 10.1371/journal.pone.0167017. eCollection 2016.

19.

Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2017 Jan;66(1):252-253. doi: 10.1016/j.jhep.2016.10.021. Epub 2016 Nov 15. No abstract available.

PMID:
27863814
20.

Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft-host interaction.

Mirza N, Zierhut M, Korn A, Bornemann A, Vogel W, Schmid-Horch B, Bethge WA, Stevanović S, Salih HR, Kanz L, Rammensee HG, Haen SP.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13827-13832. Epub 2016 Nov 10.

21.

On-road vehicle emissions and their control in China: A review and outlook.

Wu Y, Zhang S, Hao J, Liu H, Wu X, Hu J, Walsh MP, Wallington TJ, Zhang KM, Stevanovic S.

Sci Total Environ. 2017 Jan 1;574:332-349. doi: 10.1016/j.scitotenv.2016.09.040. Epub 2016 Oct 14.

PMID:
27639470
22.

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Klatt MG, Kowalewski DJ, Schuster H, Di Marco M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Oncoimmunology. 2016 Jun 30;5(8):e1204504. doi: 10.1080/2162402X.2016.1204504. eCollection 2016 Aug.

23.

Toll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants.

Hanzelmann D, Joo HS, Franz-Wachtel M, Hertlein T, Stevanovic S, Macek B, Wolz C, Götz F, Otto M, Kretschmer D, Peschel A.

Nat Commun. 2016 Jul 29;7:12304. doi: 10.1038/ncomms12304.

24.

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.

Peper JK, Bösmüller HC, Schuster H, Gückel B, Hörzer H, Roehle K, Schäfer R, Wagner P, Rammensee HG, Stevanović S, Fend F, Staebler A.

Oncoimmunology. 2015 Jul 1;5(5):e1065369. doi: 10.1080/2162402X.2015.1065369. eCollection 2016 May.

25.

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7.

26.

Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets.

Glisic S, Sencanski M, Perovic V, Stevanovic S, García-Sosa AT.

Molecules. 2016 May 5;21(5). pii: E589. doi: 10.3390/molecules21050589.

27.

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.

Kowalewski DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee HG, Stevanović S, Stickel JS.

Blood Cancer J. 2016 Apr 8;6:e411. doi: 10.1038/bcj.2016.14.

28.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2016 Apr;30(4):1003-4. doi: 10.1038/leu.2016.1. No abstract available.

PMID:
27049048
29.

Excreted Cytoplasmic Proteins Contribute to Pathogenicity in Staphylococcus aureus.

Ebner P, Rinker J, Nguyen MT, Popella P, Nega M, Luqman A, Schittek B, Di Marco M, Stevanovic S, Götz F.

Infect Immun. 2016 May 24;84(6):1672-81. doi: 10.1128/IAI.00138-16. Print 2016 Jun. Erratum in: Infect Immun. 2017 Nov 17;85(12 ):.

30.

Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.

Bösmüller HC, Wagner P, Peper JK, Schuster H, Pham DL, Greif K, Beschorner C, Rammensee HG, Stevanović S, Fend F, Staebler A.

Int J Gynecol Cancer. 2016 May;26(4):671-9. doi: 10.1097/IGC.0000000000000672.

PMID:
26905331
31.

Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells.

Palesch D, Wagner J, Meid A, Molenda N, Sienczyk M, Burkhardt J, Münch J, Prokop L, Stevanovic S, Westhoff MA, Halatsch ME, Wirtz CR, Zimecki M, Burster T.

Cancer Immunol Immunother. 2016 Mar;65(3):283-91. doi: 10.1007/s00262-016-1798-5. Epub 2016 Feb 2.

PMID:
26837514
32.

Influence of oxygen content of the certain types of biodiesels on particulate oxidative potential.

Hedayat F, Stevanovic S, Milic A, Miljevic B, Nabi MN, Zare A, Bottle SE, Brown RJ, Ristovski ZD.

Sci Total Environ. 2016 Mar 1;545-546:381-8. doi: 10.1016/j.scitotenv.2015.12.036. Epub 2015 Dec 31.

PMID:
26748002
33.

TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.

Hermann C, van Hateren A, Trautwein N, Neerincx A, Duriez PJ, Stevanović S, Trowsdale J, Deane JE, Elliott T, Boyle LH.

Elife. 2015 Oct 6;4. pii: e09617. doi: 10.7554/eLife.09617.

34.

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.

Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS.

Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341.

35.

Antimicrobial Activity of Molluscan Hemocyanins from Helix and Rapana Snails.

Dolashka P, Dolashki A, Van Beeumen J, Floetenmeyer M, Velkova L, Stevanovic S, Voelter W.

Curr Pharm Biotechnol. 2016;17(3):263-70.

PMID:
26343131
36.

Identification of a Novel Immunodominant HLA-B*07: 02-restricted Adenoviral Peptide Epitope and Its Potential in Adoptive Transfer Immunotherapy.

Günther PS, Peper JK, Faist B, Kayser S, Hartl L, Feuchtinger T, Jahn G, Neuenhahn M, Busch DH, Stevanović S, Dennehy KM.

J Immunother. 2015 Sep;38(7):267-75. doi: 10.1097/CJI.0000000000000087.

PMID:
26261890
37.

Structure and Characterization of Eriphia verrucosa Hemocyanin.

Dolashki A, Radkova M, Todorovska E, Ivanov M, Stevanovic S, Molin L, Traldi P, Voelter W, Dolashka P.

Mar Biotechnol (NY). 2015 Dec;17(6):743-52. doi: 10.1007/s10126-015-9653-9. Epub 2015 Aug 11.

PMID:
26256301
38.

Particle emissions from microalgae biodiesel combustion and their relative oxidative potential.

Rahman MM, Stevanovic S, Islam MA, Heimann K, Nabi MN, Thomas G, Feng B, Brown RJ, Ristovski ZD.

Environ Sci Process Impacts. 2015 Sep;17(9):1601-10. doi: 10.1039/c5em00125k. Epub 2015 Aug 4.

PMID:
26238214
39.

Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy.

Kayser S, Boβ C, Feucht J, Witte KE, Scheu A, Bülow HJ, Joachim S, Stevanović S, Schumm M, Rittig SM, Lang P, Röcken M, Handgretinger R, Feuchtinger T.

Oncoimmunology. 2015 May 21;4(5):e1002723. eCollection 2015 May.

40.

An open-source computational and data resource to analyze digital maps of immunopeptidomes.

Caron E, Espona L, Kowalewski DJ, Schuster H, Ternette N, Alpízar A, Schittenhelm RB, Ramarathinam SH, Lindestam Arlehamn CS, Chiek Koh C, Gillet LC, Rabsteyn A, Navarro P, Kim S, Lam H, Sturm T, Marcilla M, Sette A, Campbell DS, Deutsch EW, Moritz RL, Purcell AW, Rammensee HG, Stevanovic S, Aebersold R.

Elife. 2015 Jul 8;4. doi: 10.7554/eLife.07661.

41.

Antileukemia T-cell responses in CLL - We don't need no aberration.

Kowalewski DJ, Stevanovic S, Rammensee HG, Stickel JS.

Oncoimmunology. 2015 Mar 16;4(7):e1011527. eCollection 2015 Jul.

42.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Blood. 2015 Sep 3;126(10):1203-13. doi: 10.1182/blood-2015-04-640532. Epub 2015 Jul 2. Erratum in: Blood. 2015 Oct 22;126(17):2072-3.

43.

High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus- and tumor-derived antigens.

Wegner J, Hackenberg S, Scholz CJ, Chuvpilo S, Tyrsin D, Matskevich AA, Grigoleit GU, Stevanović S, Hünig T.

Blood. 2015 Jul 9;126(2):185-94. doi: 10.1182/blood-2015-01-622704. Epub 2015 May 29.

44.

Proton pump (H+/K+-ATPase) expression in human larynx.

Stevanović S, Radić R, Kačarević ŽP, Bedeković V, Aras I, Baudoin T, Šoš D, Vrselja Z, Ivkić M.

Auris Nasus Larynx. 2015 Dec;42(6):458-62. doi: 10.1016/j.anl.2015.04.013. Epub 2015 May 21.

PMID:
26003879
45.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2015 May;64(5):585-98. doi: 10.1007/s00262-014-1649-1. Epub 2015 Feb 18.

46.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.

J Clin Oncol. 2015 May 10;33(14):1543-50. doi: 10.1200/JCO.2014.58.9093. Epub 2015 Mar 30.

47.

A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.

Peper JK, Stevanović S.

Cancer Immunol Immunother. 2015 Oct;64(10):1295-303. doi: 10.1007/s00262-015-1682-8. Epub 2015 Mar 31. Review.

PMID:
25822767
48.

Changes in the gene expression profile of the bladder cancer cell lines after treatment with Helix lucorum and Rapana venosa hemocyanin.

Antonova O, Yossifova L, Staneva R, Stevanovic S, Dolashka P, Toncheva D.

J BUON. 2015 Jan-Feb;20(1):180-7.

PMID:
25778314
49.

Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P, Salih HR.

Leukemia. 2015 Aug;29(8):1676-83. doi: 10.1038/leu.2015.50. Epub 2015 Feb 24.

PMID:
25710310
50.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6.

Supplemental Content

Loading ...
Support Center